FI76340C - Foerfarande foer framstaellning av terapeutiskt anvaendbara nya 6-amino-7-hydroxi-4,5,6,7-tetrahydroimidazo- /4,5,1-j-k/-/1/bensazepin-2-(1h)-on-derivat och deras salter. - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara nya 6-amino-7-hydroxi-4,5,6,7-tetrahydroimidazo- /4,5,1-j-k/-/1/bensazepin-2-(1h)-on-derivat och deras salter. Download PDFInfo
- Publication number
- FI76340C FI76340C FI833697A FI833697A FI76340C FI 76340 C FI76340 C FI 76340C FI 833697 A FI833697 A FI 833697A FI 833697 A FI833697 A FI 833697A FI 76340 C FI76340 C FI 76340C
- Authority
- FI
- Finland
- Prior art keywords
- compound
- radical
- formula
- hydroxy
- amino
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 34
- -1 alkyl radical Chemical class 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- 150000001350 alkyl halides Chemical class 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 2
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical compound O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 claims description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 abstract description 3
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- JJFWDSAUXLLXOO-UHFFFAOYSA-N 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,l-j-k][1]-benzazepin-2(1h)-one Chemical class OC1C(N)CCN2C(=O)NC3=CC=CC1=C32 JJFWDSAUXLLXOO-UHFFFAOYSA-N 0.000 abstract 1
- 230000002959 anti-hypotensive effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000005119 centrifugation Methods 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 239000005457 ice water Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- FJZLANUAMGHEGO-UHFFFAOYSA-N 1,3-dihydro-1-benzazepin-2-one Chemical compound N1C(=O)CC=CC2=CC=CC=C21 FJZLANUAMGHEGO-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NSFSAHIOBUAWGP-UHFFFAOYSA-N 2-n,2-n-diphenylbenzene-1,2-diamine Chemical compound NC1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 NSFSAHIOBUAWGP-UHFFFAOYSA-N 0.000 description 1
- XFFILAFLGDUMBF-UHFFFAOYSA-N 2-phenoxyacetaldehyde Chemical compound O=CCOC1=CC=CC=C1 XFFILAFLGDUMBF-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AUGPRLHZAOPVIR-UHFFFAOYSA-N 3-benzyl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1CC1=CC=CC=C1 AUGPRLHZAOPVIR-UHFFFAOYSA-N 0.000 description 1
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XFASJWLBXHWUMW-UHFFFAOYSA-N 3-prop-1-en-2-yl-1h-benzimidazol-2-one Chemical compound C1=CC=C2NC(=O)N(C(=C)C)C2=C1 XFASJWLBXHWUMW-UHFFFAOYSA-N 0.000 description 1
- PTNUQSFEJXMNOQ-UHFFFAOYSA-N 4-(2-oxo-3h-benzimidazol-1-yl)butanoic acid Chemical compound C1=CC=C2NC(=O)N(CCCC(=O)O)C2=C1 PTNUQSFEJXMNOQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- XEKAUTDWPYQNFU-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl XEKAUTDWPYQNFU-UHFFFAOYSA-N 0.000 description 1
- 230000005794 circulatory dysfunction Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MLFOVEYKMYRRRN-UHFFFAOYSA-N ethyl 4-(2-oxo-3h-benzimidazol-1-yl)butanoate Chemical compound C1=CC=C2NC(=O)N(CCCC(=O)OCC)C2=C1 MLFOVEYKMYRRRN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI870930A FI870930L (fi) | 1982-10-12 | 1983-10-11 | Foerfarande foer framstaellning av 4,5-dihydroimidazo/4,5,1-j-k//1/benzazepin-2,7-(1h,6h) dion. |
| FI861730A FI76341C (fi) | 1982-10-12 | 1986-04-24 | Foerfarande foer framstaellning av 5,6-dihydroimidazo/4,5,1-j-k//1/benzazepin-2,7(1h,4h)-dion. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8217054 | 1982-10-12 | ||
| FR8217054A FR2534257A1 (fr) | 1982-10-12 | 1982-10-12 | Nouveaux derives de la 6-amino 7-hydroxy 4,5,6,7-tetrahydro-imidazo/4,5,1-j-k/ /1/ benzazepin-2(1h)-one, leurs sels, application a titre de medicaments, compositions les renfermant et un intermediaire |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI833697A0 FI833697A0 (fi) | 1983-10-11 |
| FI833697L FI833697L (fi) | 1984-04-13 |
| FI76340B FI76340B (fi) | 1988-06-30 |
| FI76340C true FI76340C (fi) | 1988-10-10 |
Family
ID=9278183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI833697A FI76340C (fi) | 1982-10-12 | 1983-10-11 | Foerfarande foer framstaellning av terapeutiskt anvaendbara nya 6-amino-7-hydroxi-4,5,6,7-tetrahydroimidazo- /4,5,1-j-k/-/1/bensazepin-2-(1h)-on-derivat och deras salter. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4585770A (instruction) |
| EP (1) | EP0107569B1 (instruction) |
| JP (1) | JPS59130289A (instruction) |
| KR (1) | KR900006753B1 (instruction) |
| AT (1) | ATE25981T1 (instruction) |
| AU (1) | AU559422B2 (instruction) |
| CA (2) | CA1216847A (instruction) |
| DD (1) | DD215784A5 (instruction) |
| DE (1) | DE3370332D1 (instruction) |
| DK (1) | DK163734C (instruction) |
| ES (1) | ES8405802A1 (instruction) |
| FI (1) | FI76340C (instruction) |
| FR (1) | FR2534257A1 (instruction) |
| GR (1) | GR78731B (instruction) |
| HU (1) | HU188499B (instruction) |
| IE (1) | IE59441B1 (instruction) |
| IL (1) | IL69993A (instruction) |
| MX (1) | MX8495A (instruction) |
| NZ (1) | NZ205918A (instruction) |
| PH (1) | PH20031A (instruction) |
| PT (1) | PT77469B (instruction) |
| SU (2) | SU1287753A3 (instruction) |
| ZA (1) | ZA837480B (instruction) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608046B1 (fr) * | 1986-12-11 | 1989-03-31 | Roussel Uclaf | Compositions zootechniques renfermant un derive de la 6-amino 7-hydroxy 4,5,6,7-tetrahydroimidazo /4,5, 1-j-k/ /1/benzazepin-2-(1h)-one |
| FR2608047B1 (fr) * | 1986-12-11 | 1990-08-31 | Roussel Uclaf | Compositions zootechniques renfermant un derive de la 6-amino 7-hydroxy 4,5,6,7-tetrahydroimidazo /4,5,1-j-k/ /1/ benzazepin-2-(1h)-one |
| HU203667B (en) * | 1986-12-11 | 1991-09-30 | Roussel Uclaf | Process for producing synergetic zootechnical compositions containing three components |
| AU616390B2 (en) * | 1986-12-11 | 1991-10-31 | Hoechst Roussel Vet S.A. | Zootechnical compositions containing a beta-adrenergic |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| IL93136A (en) * | 1989-02-23 | 1995-01-24 | Janssen Pharmaceutica Nv | Tetrahydroimidazo (1,4) benzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them |
| PT708776E (pt) * | 1993-07-13 | 2001-06-29 | Janssen Pharmaceutica Nv | Imidazoazepinas anti-alergicas |
| FR2735474B1 (fr) * | 1995-06-13 | 1997-08-08 | Roussel Uclaf | Chlorhydrate de zilpaterol sous une forme cristallisee particuliere, son procede de preparation et les produits intermediaires mis en oeuvre |
| US7207289B2 (en) * | 2004-05-20 | 2007-04-24 | Intervet International B.V. | Method of feeding the cattle with feed additives that increases beef production and reduces liver abscess |
| DE602007013081D1 (de) * | 2006-10-13 | 2011-04-21 | Pfizer Ltd | Als anabole mittel für vieh geeignete heterozyklische verbindungen |
| WO2008050207A1 (en) * | 2006-10-25 | 2008-05-02 | Pfizer Limited | Heterocyclic compounds useful as anabolic agents for livestock animals |
| EP2109614B1 (en) * | 2007-02-01 | 2014-08-06 | Intervet International B.V. | Enantioselective synthesis of 6-amino-7-hydroxy-4, 5, 6, 7-tetrahydro-imidazo [4, 5, 1-jk][1]-benzazepin-2 [1h]-one and zilpaterol |
| HUE028171T2 (en) * | 2007-03-31 | 2016-12-28 | Intervet Int Bv | Methods for preparing zilpaterol and its salts |
| RU2442786C2 (ru) * | 2007-03-31 | 2012-02-20 | Интервет Интернэшнл Б.В. | Способы получения зилпатерола и его солей |
| JP5856990B2 (ja) * | 2007-03-31 | 2016-02-10 | インターベット インターナショナル ベー． フェー． | ジルパテロールおよびこの塩の製造方法 |
| MX2009010499A (es) * | 2007-03-31 | 2009-10-19 | Intervet Int Bv | Procesos para elaborar zilpaterol y sales del mismo. |
| EP1995248A1 (en) * | 2007-05-23 | 2008-11-26 | Evonik Degussa GmbH | Process for the production of amino alcohols by asymmetric hydrogenation |
| BRPI0820591A2 (pt) | 2007-12-06 | 2015-06-16 | Intervet Int Bv | Método para melhorar eficiência de utilização de ração ou aumentar a taxa de ganho de peso em um animal, composição, ração de ruminante, e kit para administrar zilpaterol (ou um sal do mesmo) e acetato de melengestrol a um animal. |
| TW201033217A (en) * | 2008-12-17 | 2010-09-16 | Intervet Int Bv | Process for making a crystalline zilpaterol salt |
| BR112014028449A2 (pt) | 2012-05-18 | 2017-06-27 | Intervet Int Bv | método para intensificar o desempenho de frangos de corte. |
| BR112015014342B1 (pt) | 2012-12-18 | 2022-10-11 | Intervet International B.V | Métodos de preparar um composto |
| WO2014140237A1 (en) | 2013-03-15 | 2014-09-18 | Intervet International B.V. | A method of improving the efficiency of beef production from bovine animals |
| CN104418808A (zh) * | 2013-09-11 | 2015-03-18 | 中美华世通生物医药科技（武汉）有限公司 | 一种适于工业化生产的中间体Buzolic acid的制备方法 |
| CN103554113B (zh) * | 2013-09-25 | 2016-04-27 | 湖北美天生物科技有限公司 | 一种盐酸齐帕特罗的合成方法 |
| RU2018105703A (ru) | 2015-07-21 | 2019-08-22 | Интервет Интернэшнл Б.В. | Новый состав премикса для животных на основе зилпатерола |
| EP3488705A1 (en) | 2017-11-23 | 2019-05-29 | Saviela AG | Solubilized growth promoting product to be applied orally to animals and method for the respective feed preparation |
| CN108752352B (zh) * | 2018-04-18 | 2019-11-26 | 江苏凌云药业股份有限公司 | 一种盐酸齐帕特罗的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2320439A (en) * | 1943-06-01 | Bottle carrier | ||
| US3200123A (en) * | 1962-01-26 | 1965-08-10 | Richardson Merreil Inc | Imidazoquinolines |
| DE3161072D1 (en) * | 1980-02-26 | 1983-11-10 | Roussel Uclaf | Cycloheptindolol derivatives and their acid-addition salts, their preparation, their use as medicines and composition containing them |
-
1982
- 1982-10-12 FR FR8217054A patent/FR2534257A1/fr active Granted
-
1983
- 1983-10-06 ZA ZA837480A patent/ZA837480B/xx unknown
- 1983-10-07 PT PT77469A patent/PT77469B/pt unknown
- 1983-10-10 MX MX849583A patent/MX8495A/es unknown
- 1983-10-10 PH PH29679A patent/PH20031A/en unknown
- 1983-10-10 GR GR72650A patent/GR78731B/el unknown
- 1983-10-11 DK DK466483A patent/DK163734C/da not_active IP Right Cessation
- 1983-10-11 HU HU833516A patent/HU188499B/hu unknown
- 1983-10-11 EP EP83401976A patent/EP0107569B1/fr not_active Expired
- 1983-10-11 AT AT83401976T patent/ATE25981T1/de not_active IP Right Cessation
- 1983-10-11 NZ NZ205918A patent/NZ205918A/en unknown
- 1983-10-11 IE IE238783A patent/IE59441B1/en not_active IP Right Cessation
- 1983-10-11 FI FI833697A patent/FI76340C/fi not_active IP Right Cessation
- 1983-10-11 DD DD83255575A patent/DD215784A5/de not_active IP Right Cessation
- 1983-10-11 ES ES526390A patent/ES8405802A1/es not_active Expired
- 1983-10-11 CA CA000438689A patent/CA1216847A/fr not_active Expired
- 1983-10-11 DE DE8383401976T patent/DE3370332D1/de not_active Expired
- 1983-10-11 SU SU833654552A patent/SU1287753A3/ru active
- 1983-10-11 AU AU20053/83A patent/AU559422B2/en not_active Expired
- 1983-10-12 JP JP58189419A patent/JPS59130289A/ja active Granted
- 1983-10-12 KR KR1019830004826A patent/KR900006753B1/ko not_active Expired
- 1983-10-12 US US06/541,085 patent/US4585770A/en not_active Expired - Lifetime
- 1983-10-18 IL IL69993A patent/IL69993A/xx not_active IP Right Cessation
-
1986
- 1986-01-30 SU SU864015498A patent/SU1384201A3/ru active
- 1986-03-17 CA CA000504318A patent/CA1222246A/fr not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI76340C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara nya 6-amino-7-hydroxi-4,5,6,7-tetrahydroimidazo- /4,5,1-j-k/-/1/bensazepin-2-(1h)-on-derivat och deras salter. | |
| SI9111599A (sl) | Postopek za pridobivanje vodotopnih analogov kamptotecina in intermediatov za njihovo pripravo, kot tudi spojine, ki jih dobimo s tem postopkom | |
| US4663326A (en) | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs | |
| JP3116230B2 (ja) | 三環式縮合ピリミジン誘導体 | |
| SK129799A3 (en) | Tetrahydropyridine compounds, pharmaceutical composition containing them and their use | |
| EP1768985B1 (fr) | Derives de pyrimido-benzimidazole et leur utilisation comme agonistes ou antgonistes des récepteurs des mélanocortines | |
| US4767755A (en) | 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivatives and pharmaceutical compositions | |
| DD253821A5 (de) | Verfahren zur herstellung von pyrrolo-benzimidozolen, pyrrolo-benzooxazolen und pyrrolo-benzthiozole | |
| US3666762A (en) | 2{40 {62 -ISOPROPYL-5{40 {60 -n-PROPYL-9,10-DIHYDRO-ERGOPEPTINES | |
| SU1396965A3 (ru) | Способ получени производных имидазола или их солей с кислотами | |
| SK13597A3 (en) | New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments | |
| NZ213014A (en) | Imidazo(1,2-a) quinoline derivatives and pharmaceutical compositions | |
| EP0290003A2 (de) | Neue Imidazole | |
| EP0234970B1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
| EP0638570A1 (en) | Tricyclic compound having antiallergic effect | |
| US4307102A (en) | Phenanthro[2,3-c]pyrazole | |
| US4303660A (en) | Pyrazolo[1,5-c]quinazoline derivatives and analgesic compositions containing them | |
| US4734430A (en) | Dipyrazoles and their use as bronchodilators | |
| US4609657A (en) | Ergot peptide alkaloid derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| US4372956A (en) | 5, 10-Dihydroimidazo[2,1-b]quinazolines and pharmaceutical compositions containing them | |
| US5527908A (en) | Pyrazolothiazolopyrimidine derivatives | |
| JPH10505332A (ja) | アシルイミダゾピリジン | |
| US20030181722A1 (en) | LK6-A derivatives | |
| EP0058841A2 (en) | Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof | |
| US4883876A (en) | Acylated vincaminic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |
Owner name: HOECHST ROUSSEL VET S.A. |